Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.31 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.31 |
| ▸ | CPT1A | P50416 | 8/20 | 0.33 |
| ▸ | CPT2 | P23786 | 4/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.31 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593480 | 0.92 | CPT1A (0.35) | CPT1ACPT2GABRA1GABRG2GABRB3 | |
| SCHEMBL3592264 | 0.92 | CPT1A (0.33) | CPT1ACPT2GABRA1GABRG2GABRB3 | |
| SCHEMBL3581098 | 0.90 | CPT1A (0.33) | CPT1ACPT2GABRA1GABRG2GABRB3 | |
| SCHEMBL3576368 | 0.89 | KDM4E (0.35) | CPT1ACPT2GRIN2BCPT1BKDM4E | |
| SCHEMBL3576341 | 0.85 | PDE4B (0.34) | CPT1ACPT2GABRA1GABRG2GABRB3 | |
| SCHEMBL3581779 | 0.84 | TLR9 (0.34) | CPT1ACPT2GABRA1GABRG2GABRB3 | |
| SCHEMBL3585326 | 0.83 | KDM4E (0.32) | CPT1ACPT2GABRA1GABRG2GABRB3 | |
| SCHEMBL3581627 | 0.83 | IRAK4 (0.33) | CPT1ACPT2GABRA1GABRG2GABRB3 | |
| SCHEMBL3584282 | 0.82 | KCNH2 (0.34) | CPT1ACPT2GABRA1GABRG2GABRB3 | |
| SCHEMBL3589601 | 0.82 | CPT1A (0.33) | CPT1ACPT2GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | claimed |
| EP-1962605-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | GABRA1 333/4885GABRG2 514/4885GABRB3 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.